Compass Therapeutics, Inc.

NasdaqCM:CMPX Stock Report

Market Cap: US$209.1m

Compass Therapeutics Management

Management criteria checks 0/4

Compass Therapeutics' CEO is Tom Schuetz, appointed in May 2024, has a tenure of less than a year. total yearly compensation is $4.87M, comprised of 11.8% salary and 88.2% bonuses, including company stock and options. directly owns 3.82% of the company’s shares, worth $7.99M. The average tenure of the management team and the board of directors is 1.5 years and 2.9 years respectively.

Key information

Tom Schuetz

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage11.8%
CEO tenureless than a year
CEO ownership3.8%
Management average tenure1.5yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Sep 28
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20
Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

CEO Compensation Analysis

How has Tom Schuetz's remuneration changed compared to Compass Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$48m

Jun 30 2024n/an/a

-US$47m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$5mUS$575k

-US$42m

Sep 30 2023n/an/a

-US$41m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$550k

-US$39m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

-US$82m

Dec 31 2021US$5mUS$4k

-US$82m

Sep 30 2021n/an/a

-US$78m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$3mUS$4k

-US$29m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$1mUS$400k

-US$35m

Compensation vs Market: Tom's total compensation ($USD4.87M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.

CEO

Tom Schuetz (63 yo)

less than a year

Tenure

US$4,873,206

Compensation

Dr. Thomas J. Schuetz, also known as Tom, M.D., Ph.D. was co-founded of Compass Therapeutics, Inc in 2014 until 2024 and He serves as its CEO since May 28, 2024. He also served as President since May 28, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Schuetz
Chief Executive Officerless than a yearUS$4.87m3.82%
$ 8.0m
Vered Bisker-Leib
Advisorno dataUS$4.07m0.56%
$ 1.2m
Barry Shin
Chief Financial Officerno datano datano data
Jonathan Anderman
VP, Head of Legal & Corporate Secretary3.3yrsno data0.00073%
$ 1.5k
Anna Gifford
Communications Managerno datano datano data
Minori Rosales
Senior VP & Head of Clinical Development1.6yrsno datano data
Karin Herrera
VP & Head of Clinical Operations1.6yrsno datano data
James Kranz
VP and Head of Chemistry Manufacturing & Controls1.3yrsno datano data

1.5yrs

Average Tenure

57yo

Average Age

Experienced Management: CMPX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Carl Gordon
Independent Chairman9.9yrsUS$222.63k0%
$ 0
Daniel Von Hoff
Member of Clinical Advisory Board2.9yrsno datano data
Ellen Chiniara
Independent Director2.7yrsUS$163.42k0%
$ 0
Philip Ferneau
Independent Director9.9yrsUS$193.02k0%
$ 0
Richard Lindahl
Independent Director1.7yrsUS$147.92k0%
$ 0
Mary Gray
Independent Director2.7yrsUS$163.42k0%
$ 0
James Boylan
Independent Director2.1yrsUS$45.00k0%
$ 0
F. Hodi
Member of Clinical Advisory Board5.2yrsno datano data
Patricia LoRusso
Member of Clinical Advisory Board2.9yrsno datano data
Richard Goldberg
Member of Clinical Advisory Board2.9yrsno datano data
Howard Hochster
Member of Clinical Advisory Board2.9yrsno datano data

2.9yrs

Average Tenure

62yo

Average Age

Experienced Board: CMPX's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 22:37
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Compass Therapeutics, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.